Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
TN

NASDAQ · TNXP

Tonix Pharmaceuticals Holding Corp.

Healthcare · Biotechnology

$8.91

Down-$0.32 (-3.47%)

Updated Oct 3, 2026, 9:14 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.07M
P/E ratio
-2.71
Dividend yield
0.00%
52-week range
$9.19 – $17.00
Volume
803.1K
Avg. volume
886.98K

Price performance · TNXP

TNXP price history

1M range · 0 trading sessions · Daily adjusted prices

TNXP does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest TNXP news

The latest Smart Investors Daily articles mentioning TNXP.

Stock researchCompany · Overview

TNXP research

Overview

Company profile and research snapshot.

Company profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TNXP recent ratings
DateFirmRatingTarget
Jun 25, 2026Raymond JamesStrong Buy—
May 4, 2026TD CowenBuy—
Mar 20, 2025Noble Capital MarketsOutperform—
Jul 22, 2024Alliance Global PartnersBuy—
Feb 28, 2024Dawson JamesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second

Yahoo · Sep 12, 2026

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and

Yahoo · Sep 8, 2026

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Mr. Englese’s leadership of Tonix’s commercial organization since 2024 has included the go-to-market strategy and U.S. launch of TONMYA®, with growth across sales, managed care, and patient accessBERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By